Fraxetin inhibits the induction of anti-Fas IgM, tumor necrosis factor-α and interleukin-1β-mediated apoptosis by Fas pathway inhibition in human osteoblastic cell line MG-63

被引:14
作者
Kuo, PL [1 ]
Huang, YT
Chang, CH
Chang, JK
机构
[1] ChiaNan Univ Pharm & Sci, Dept Biotechnol, Tainan, Taiwan
[2] ChiaNan Univ Pharm & Sci, Dept Pharm, Tainan, Taiwan
关键词
fraxetin; osteoporosis; tumor necrosis factor-alpha; interleukin-1; beta; Fas;
D O I
10.1016/j.intimp.2006.02.010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The survival of osteoblast cells is one of the determinants of the development of osteoporosis in patients with inflamed synovium, such as in rheumatoid arthritis (RA). By means of alkaline phosphatase (ALP) activity and osteocalcin ELISA assay, we have shown that fraxetin exhibits a significant induction of differentiation in the human osteoblast-like cell line MG-63. In addition, we also assessed whether fraxetin affects inflammatory cytokine-mediated apoptosis in osteoblast cells. TNF-alpha or IL-1 beta enhance apoptotic DNA fragmentation in anti-Fas IgM-treated MG-63 cells by increasing Fas receptor expression. However, TNF-alpha or IL-1 beta treatment alone does not induce apoptosis. Treatment of MG-63 cells with fraxetin not only inhibited anti-Fas IgM-induced apoptosis, but also blocked the synergetic effect of anti-Fas IgM with TNF-alpha or IL-1 beta on cell death. The apoptotic inhibition of fraxetin is associated with inhibition of TNF-alpha and IL-1 beta-mediated Fas expression and enhancement of FLIP expression, resulting in a decrease of caspase-8 and caspase-3 activation. These results indicate a potential use of fraxetin in preventing osteoporosis by inhibiting inflammatory cytokine-mediated apoptosis in osteoblast cells. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:1167 / 1175
页数:9
相关论文
共 29 条
  • [1] Mechanisms of disease: Cytokine pathways and joint inflammation in rheumatoid arthritis.
    Choy, EHS
    Panayi, GS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (12) : 907 - 916
  • [2] Apoptosis in autoimmune diseases
    Eguchi, K
    [J]. INTERNAL MEDICINE, 2001, 40 (04) : 275 - 284
  • [3] Antioxidant activity of fraxetin:: In vivo and ex vivo parameters in normal situation versus induced stress
    Fernández-Puntero, B
    Barroso, I
    Iglesias, I
    Benedi, J
    Villar, A
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2001, 24 (07) : 777 - 784
  • [4] Control of osteoblast function and regulation of bone mass
    Harada, S
    Rodan, GA
    [J]. NATURE, 2003, 423 (6937) : 349 - 355
  • [5] The biochemistry of apoptosis
    Hengartner, MO
    [J]. NATURE, 2000, 407 (6805) : 770 - 776
  • [6] Osteoblast apoptosis and bone turnover
    Hock, JM
    Krishnan, V
    Onyia, JE
    Bidwell, JP
    Milas, J
    Stanislaus, D
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (06) : 975 - 984
  • [7] Acacetin inhibits the proliferation of Hep G2 by blocking cell cycle progression and inducing apoptosis
    Hsu, YL
    Kuo, PL
    Lin, CC
    [J]. BIOCHEMICAL PHARMACOLOGY, 2004, 67 (05) : 823 - 829
  • [8] Daidzein enhances osteoblast growth that may be mediated by increased bone morphogenetic protein (BMP) production
    Jia, TL
    Wang, HZ
    Xie, LP
    Wang, XY
    Zhang, RQ
    [J]. BIOCHEMICAL PHARMACOLOGY, 2003, 65 (05) : 709 - 715
  • [9] Fas and Fas ligand interaction is necessary for human osteoblast apoptosis
    Kawakami, A
    Eguchi, K
    Matsuoka, N
    Tsuboi, M
    Koji, T
    Urayama, S
    Fujiyama, K
    Kiriyama, T
    Nakashima, T
    Nakane, PK
    Nagataki, S
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (10) : 1637 - 1646
  • [10] KIMURA Y, 1985, BIOCHIM BIOPHYS ACTA, V834, P224